Home
Storia in 2 fonti
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.
- ·
economictimes.indiatimes.com
Apollo Hospitals Q4 Results: Cons PAT jumps 36% YoY to Rs 529 crore, revenue rises 18%; Rs 10 per share dividend declared
Apollo Hospitals reported strong Q4 FY26 results: consolidated PAT surged 36% YoY to Rs 529 crore, and revenue increased 18% to Rs 6,605 crore. EBITDA grew 31% to Rs 1,011 crore.…
- ·
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages…
- ·
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore…
- ·
thehindubusinessline.com
Sun Pharma Q4 net profit up 26% at ₹2,714 crore
Sun Pharma's Q4 net profit rises 26% to ₹2,714 crore, driven by robust formulation sales and strong overall revenue growth.